Greg Frank
Dr Gregory Frank, Director of Infectious Disease Policy, Biotechnology Innovation Organization (BIO.org), and board member of the AMR Industry Alliance. Greg Frank is responsible for BIO’s antimicrobial resistance (AMR), vaccine regulatory, and vaccine reimbursement policy. His role includes leading a group of 50 BIO member companies to develop policy solutions that address AMR. Dr Frank also serves on the expert advisory committees of the Access to Medicines Foundation AMR Benchmark, the Global AMR R&D Hub, and the Duke-Margolis Center for Health Policy Antimicrobial Incentives & Payment Reform Project. He also is the Director of the Working to Fight AMR public …
Dr Gregory Frank, Director of Infectious Disease Policy, Biotechnology Innovation Organization (BIO.org), and board member of the AMR Industry Alliance.
Greg Frank is responsible for BIO’s antimicrobial resistance (AMR), vaccine regulatory, and vaccine reimbursement policy. His role includes leading a group of 50 BIO member companies to develop policy solutions that address AMR. Dr Frank also serves on the expert advisory committees of the Access to Medicines Foundation AMR Benchmark, the Global AMR R&D Hub, and the Duke-Margolis Center for Health Policy Antimicrobial Incentives & Payment Reform Project. He also is the Director of the Working to Fight AMR public awareness campaign.
Prior to joining BIO, Dr. Frank served as Program Officer for Science and Research policy at the Infectious Diseases Society of America (IDSA), where Dr. Frank led policy initiatives on the infectious disease physician scientist workforce, dual use research of concern, and improving the development and clinical integration of infectious disease diagnostics that can address AMR.
Dr Frank received his doctorate in immunology at the University of Pittsburgh and pursued his postdoctoral training at the Laboratory of Viral Diseases at the National Institute of Allergy & Infectious Diseases. He has published multiple scientific articles in the field of infectious disease.
See more
Greg Frank is responsible for BIO’s antimicrobial resistance (AMR), vaccine regulatory, and vaccine reimbursement policy. His role includes leading a group of 50 BIO member companies to develop policy solutions that address AMR. Dr Frank also serves on the expert advisory committees of the Access to Medicines Foundation AMR Benchmark, the Global AMR R&D Hub, and the Duke-Margolis Center for Health Policy Antimicrobial Incentives & Payment Reform Project. He also is the Director of the Working to Fight AMR public awareness campaign.
Prior to joining BIO, Dr. Frank served as Program Officer for Science and Research policy at the Infectious Diseases Society of America (IDSA), where Dr. Frank led policy initiatives on the infectious disease physician scientist workforce, dual use research of concern, and improving the development and clinical integration of infectious disease diagnostics that can address AMR.
Dr Frank received his doctorate in immunology at the University of Pittsburgh and pursued his postdoctoral training at the Laboratory of Viral Diseases at the National Institute of Allergy & Infectious Diseases. He has published multiple scientific articles in the field of infectious disease.
Articles: Greg Frank
The Fight Against Superbugs: Properly Incentivising Antimicrobial R&D Is Key
Opinion / BIO’s Greg Frank outlines the alarming growth of drug-resistant infections and the steps that need to be taken to combat this rapidly emerging global health threat. Drug-resistant superbugs are evolving at a rapid pace. In fact, it is estimated that 700,000 people die from drug-resistant infections each year. Without urgent action, that number is…
Latest Report
